<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00133</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Section III&hyph;A&hyph;1. Deliberate transfer of a drug resistance trait to microorganisms  <!-- PJG 0012 frnewline --> that are not known to acquire the trait naturally (see Section V&hyph;B), if such  <!-- PJG 0012 frnewline --> acquisition could compromise the use of the drug to control disease agents in  <!-- PJG 0012 frnewline --> humans, veterinary medicine, or agriculture.  <!-- PJG 0012 frnewline --> Section III&hyph;A&hyph;2. Certain experiments involving the deliberate transfer of  <!-- PJG 0012 frnewline --> recombinant DNA or DNA or RNA derived from recombinant DNA into one or  <!-- PJG 0012 frnewline --> more human subjects (see Section V&hyph;U) shall be considered Major Actions (see  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1) and Appendix M&hyph;III), and shall require RAC review and NIH  <!-- PJG 0012 frnewline --> Director approval, if determined by NIH/ORDA, in consultation with the RAC  <!-- PJG 0012 frnewline --> Chair and one or more RAC members, as necessary, to: (i) represent novel  <!-- PJG 0012 frnewline --> characteristics (e.g., target disease or vector), (ii) represent an uncertain degree of  <!-- PJG 0012 frnewline --> risk to human health or the environment, or (iii) contain information determined  <!-- PJG 0012 frnewline --> to require further public review. The requirement for RAC review shall not be  <!-- PJG 0012 frnewline --> considered to preempt any other required review or approval of experiments with  <!-- PJG 0012 frnewline --> one or more human subjects. Relevant Institutional Biosafety Committee and  <!-- PJG 0012 frnewline --> Institutional Review Board reviews and approvals of the proposal should be  <!-- PJG 0012 frnewline --> completed before submission to NIH. Certain experiments involving deliberate  <!-- PJG 0012 frnewline --> transfer of recombinant DNA or DNA or RNA derived from recombinant DNA  <!-- PJG 0012 frnewline --> into one or more human subjects may qualify for the Accelerated Review process  <!-- PJG 0012 frnewline --> (see Section III&hyph;B&hyph;2). Certain categories of experiments involving the deliberate  <!-- PJG 0012 frnewline --> transfer of recombinant DNA or DNA or RNA derived from recombinant DNA  <!-- PJG 0012 frnewline --> into one or more human subjects and that are not covered by Section V&hyph;U, may be  <!-- PJG 0012 frnewline --> considered exempt from RAC and/or NIH/ORDA review and/or NIH Director  <!-- PJG 0012 frnewline --> approval and only require registration with NIH/ORDA (see Section III&hyph;C&hyph;7).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III&hyph;B. Experiments That Require NIH/ORDA and Institutional Biosafety  <!-- PJG 0012 frnewline --> Committee Approval Before Initiation  <!-- PJG 0012 frnewline --> Section III&hyph;B&hyph;1. Experiments Involving the Cloning of Toxin Molecules with LD <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=2 --> 50 <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 -->  of Less Than 100 Nanograms per Kilogram Body Weight  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Deliberate formation of recombinant DNA containing genes for the biosynthesis  <!-- PJG 0012 frnewline --> of toxin molecules lethal for vertebrates at an LD <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 50 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of less than 100 nanograms per  <!-- PJG 0012 frnewline --> kilogram body weight (e.g., microbial toxins such as the botulinum toxins, tetanus  <!-- PJG 0012 frnewline --> toxin, diphtheria toxin, and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Shigella dysenteriae  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> neurotoxin). Specific approval has  <!-- PJG 0012 frnewline --> been given for the cloning in  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Escherichia coli  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> K&hyph;12 of DNA containing genes coding  <!-- PJG 0012 frnewline --> for the biosynthesis of toxic molecules which are lethal to vertebrates at 100  <!-- PJG 0012 frnewline --> nanograms to 100 micrograms per kilogram body weight. Specific experiments  <!-- PJG 0012 frnewline --> already approved under this section may be obtained from the Office of  <!-- PJG 0012 frnewline --> Recombinant DNA Activities, National Institutes of Health, Building 31, Room  <!-- PJG 0012 frnewline --> 4B11, Bethesda, Maryland 20892, (301) 496&hyph;9838.  <!-- PJG 0012 frnewline --> Section III&hyph;B&hyph;1&hyph;(a). Experiments in this category cannot be initiated without  <!-- PJG 0012 frnewline --> submission of relevant information on the proposed experiment to NIH/ORDA.  <!-- PJG 0012 frnewline --> The containment conditions for such experiments will be determined by  <!-- PJG 0012 frnewline --> NIH/ORDA in consultation with ad hoc experts. Such experiments require  <!-- PJG 0012 frnewline --> Institutional Biosafety Committee approval before initiation (see Section IV&hyph;B&hyph;2&hyph;b&hyph;(1)).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III&hyph;B&hyph;2. Accelerated Review of Human Gene Transfer Experiments  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> As determined by NIH/ORDA, in consultation with the RAC Chair and one or  <!-- PJG 0012 frnewline --> more RAC members, as necessary, certain categories of human gene transfer  <!-- PJG 0012 frnewline --> experiments may be considered as Minor Actions and qualify for Accelerated Review  <!-- PJG 0012 frnewline --> and approval (see Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(a), Appendix M&hyph;III&hyph;A, and Appendix M&hyph;  <!-- PJG 0012 frnewline --> V). The RAC Chair will present a report of all NIH/ORDA approved human  <!-- PJG 0012 frnewline --> gene transfer protocols at the next regularly scheduled RAC meeting. If  <!-- PJG 0012 frnewline --> NIH/ORDA determines that an experiment does not qualify for the Accelerated  <!-- PJG 0012 frnewline --> Review process, the Principal Investigator must submit the proposal for full RAC review " 8 weeks prior to the next scheduled RAC meeting (See Section III&hyph;A&hyph;2).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III&hyph;B&hyph;3. Minor Modifications to Human Gene Transfer Experiments  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A minor modification in a human gene transfer protocol is a modification that  <!-- PJG 0012 frnewline --> does not significantly alter the basic design of the protocol and that does not  <!-- PJG 0012 frnewline --> increase risk to human subjects or the environment. After approval has been  <!-- PJG 0012 frnewline --> obtained by the relevant Institutional Biosafety Committee and Institutional  <!-- PJG 0012 frnewline --> Review Board, NIH/ORDA will consider the change in consultation with the RAC  <!-- PJG 0012 frnewline --> Chair and one or more RAC members, as necessary. Submit minor modifications  <!-- PJG 0012 frnewline --> to the Office of Recombinant DNA Activities, National Institutes of Health,  <!-- PJG 0012 frnewline --> Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496&hyph;9838. The RAC  <!-- PJG 0012 frnewline --> Chair will provide a report on any such approvals at the next regularly scheduled RAC meeting.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III&hyph;C. Experiments That Require Institutional Biosafety Committee  <!-- PJG 0012 frnewline --> Approval Before Initiation  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Prior to the initiation of an experiment that falls into this category, the Principal  <!-- PJG 0012 frnewline --> Investigator must submit a registration document to the Institutional Biosafety  <!-- PJG 0012 frnewline --> Committee which contains the following information: (i) The source(s) of DNA;  <!-- PJG 0012 frnewline --> (ii) the nature of the inserted DNA sequences; (iii) the host(s) and vector(s) to be  <!-- PJG 0012 frnewline --> used; (iv) if an attempt will be made to obtain expression of a foreign gene, and if  <!-- PJG 0012 frnewline --> so, indicate the protein that will be produced; and (v) the containment conditions  <!-- PJG 0012 frnewline --> that will be implemented as specified in the NIH Guidelines. For experiments in  <!-- PJG 0012 frnewline --> this category, the registration document shall be dated, signed by the Principal  <!-- PJG 0012 frnewline --> Investigator, and filed with the Institutional Biosafety Committee. The Institutional  <!-- PJG 0012 frnewline --> Biosafety Committee shall review and approve all experiments in this category  <!-- PJG 0012 frnewline --> prior to their initiation. Requests to decrease the level of containment specified  <!-- PJG 0012 frnewline --> for experiments in this category will be considered by NIH (see Section  <!-- PJG 0012 frnewline --> IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(c)).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III&hyph;C&hyph;1. Experiments Using Human or Animal Pathogens (Class 2, Class  <!-- PJG 0012 frnewline --> 3, Class 4, or Class 5 Agents (See Section V&hyph;A) as Host-Vector Systems  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Section III&hyph;C&hyph;1&hyph;a. Experiments involving the introduction of recombinant DNA  <!-- PJG 0012 frnewline --> into Class 2 agents shall be conducted at Biosafety Level (BL) 2 containment.  <!-- PJG 0012 frnewline --> Experiments with such agents shall be conducted with whole animals at BL2 or  <!-- PJG 0012 frnewline --> BL2&hyph;N (Animals) containment.  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;1&hyph;b. Experiments involving the introduction of recombinant DNA  <!-- PJG 0012 frnewline --> into Class 3 agents shall be conducted at BL3 containment. Experiments with such  <!-- PJG 0012 frnewline --> agents shall be conducted with whole animals at BL3 or BL3&hyph;N containment.  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;1&hyph;c. Experiments involving the introduction of recombinant DNA  <!-- PJG 0012 frnewline --> into Class 4 agents shall be conducted at BL4 containment. Experiments with such  <!-- PJG 0012 frnewline --> agents shall be conducted with whole animals at BL4 or BL4&hyph;N containment.  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;1&hyph;d. Containment conditions for experiments involving the  <!-- PJG 0012 frnewline --> introduction of recombinant DNA into Class 5 agents shall be set on a case-by-case basis following NIH/ORDA review. A U.S. Department of Agriculture permit is required for work with Class 5 agents (see Sections V&hyph;R and V&hyph;T). Experiments with such agents shall be conducted with whole animals at BL4 or BL4&hyph;N containment.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III&hyph;C&hyph;2. Experiments in Which DNA From Human or Animal Pathogens  <!-- PJG 0012 frnewline --> (Class 2, Class 3, Class 4, or Class 5 Agents (See Section V&hyph;A) is Cloned Into  <!-- PJG 0012 frnewline --> Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Section III&hyph;C&hyph;2&hyph;a. Experiments in which DNA from Class 2 or Class 3 agents (see  <!-- PJG 0012 frnewline --> Section V&hyph;A) is transferred into nonpathogenic prokaryotes or lower eukaryotes  <!-- PJG 0012 frnewline --> may be performed under BL2 containment. Experiments in which DNA from  <!-- PJG 0012 frnewline --> Class 4 agents is transferred into nonpathogenic prokaryotes or lower eukaryotes  <!-- PJG 0012 frnewline --> may be performed under BL2 containment after demonstration that only a totally  <!-- PJG 0012 frnewline --> and irreversibly defective fraction of the agent's genome is present in a given  <!-- PJG 0012 frnewline --> recombinant. In the absence of such a demonstration, BL4 containment shall be  <!-- PJG 0012 frnewline --> used. The Institutional Biosafety Committee may approve the specific lowering of  <!-- PJG 0012 frnewline --> containment for particular experiments to BL1. Many experiments in this category  <!-- PJG 0012 frnewline --> are exempt from the NIH Guidelines (see Section III&hyph;E). Experiments involving  <!-- PJG 0012 frnewline --> the formation of recombinant DNA for certain genes coding for molecules toxic for  <!-- PJG 0012 frnewline --> vertebrates require NIH/ORDA approval (see Section III&hyph;B&hyph;1) or shall be  <!-- PJG 0012 frnewline --> conducted under NIH specified conditions as described in Appendix F.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            